Patents by Inventor Pintong Huang

Pintong Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240094197
    Abstract: The present invention relates to a method for removing protein corona on the surface of nanometer particle. Specifically, the invention provides a method for removing protein corona of protein corona modified nanometer particle, the method comprises the following steps: subjecting the protein corona modified nanometer particle to ultrasound stimulation to remove the protein corona of the protein corona modified nanometer particle; the nanometer particle comprises perfluoropentane. Ultrasound stimulation can remove protein corona on the surface of nanometer particle, overcome the masking effect of the protein corona on the ligand modified on the surface of nanometer particle, and prevent the protein corona from blocking the binding of the ligand modified on the surface of nanometer particle to cell receptor.
    Type: Application
    Filed: February 19, 2023
    Publication date: March 21, 2024
    Applicant: ZHEJIANG UNIVERSITY
    Inventors: Guowei Wang, Pintong Huang, Yifan Jiang, Chao ZHANG, Tao LIN
  • Publication number: 20230358766
    Abstract: A set of serum metabolic biomarkers and detection kit for detecting tuberculosis are provided. The set of the serum metabolic biomarkers includes 17 serum metabolic biomarkers. The 17 serum metabolic biomarkers comprising D-Leucic acid, Leucinic acid, L-Cystine, MG(0:0/14:0/0:0), S-Lactoylglutathione, Octacosanoic acid, Cer(d18:1/12:0), Raffinose, LysoPC(20:1(11Z)/0:0), LysoPC(22:4(7Z,10Z,13Z,16Z)/0:0), PC(18:1(9Z)e/2:0), Torvoside G(TG(15:0/15:0/15:0)), CE(16:1(9Z)), all-trans-Heptaprenyl diphosphate, PC(15:0/16:0), NADP, TG(20:0/20:0/20:1(11Z)). The 17 serum metabolic biomarkers are verified to be associated with tuberculosis based on the level changes of these biomarkers. The tuberculosis detection model based on the levels of the 17 metabolic biomarkers can achieve an area under the ROC curve of 99.5%, sensitivity of 98.2%, and specificity of 95.8% in detecting tuberculosis.
    Type: Application
    Filed: July 12, 2023
    Publication date: November 9, 2023
    Applicant: Zhejiang SUKEAN Pharmaceutical Co., Ltd.
    Inventors: Pintong HUANG, Yajing LIU, Yan SU, Chao ZHANG
  • Publication number: 20230349900
    Abstract: A set of serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis are provided. The set of the serum metabolic biomarkers includes 17 serum metabolic biomarkers. The 17 serum metabolic biomarkers are verified to be associated with tuberculosis based on the level changes of these biomarkers. The 17 metabolites includes taurine, homocysteine, uric acid, ascorbic acid, suberylglycine, uridine, dopamine 4-sulfate, inosinic acid, glyceraldehyde phosphate, [3-methoxy-4-(phosphoryl)phenyl]carbonyl sulfonic acid, nuclomedone, n4-cyclopropyl-6-(2,3-dichlorophenyl)-1,2,3,4-tetrahydropyrimidine-2,4-diimine, 1-[2-chlorine-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole, tetrachloro-phthalic anhydride, malotilate, fulvic acid, and L-neopterin. The serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis can assist doctors in accurately diagnosing the disease, which is of great significance for the diagnosis and mass screening for drug-resistant tuberculosis.
    Type: Application
    Filed: July 12, 2023
    Publication date: November 2, 2023
    Applicant: Zhejiang SUKEAN Pharmaceutical Co., Ltd.
    Inventors: Pintong HUANG, Yajing LIU, Yan SU, Chao ZHANG
  • Publication number: 20230287020
    Abstract: The present invention relates to an amphiphilic material and an application thereof in preparation of a liposome, and in particular, the present invention provides an amphiphilic material, wherein the structure of the amphiphilic material is as follows. The amphiphilic material of the present invention is used for preparing drug-loaded nanoparticles to effectively enter cells such as tumor cells, thereby enhancing the therapeutic effect of the drug.
    Type: Application
    Filed: April 20, 2022
    Publication date: September 14, 2023
    Applicant: ZHEJIANG UNIVERSITY
    Inventors: Guowei Wang, Pintong Huang, Yifan Jiang, Qunying Li, Chao Zhang